Science Corporation has implanted its vision-restoring chip in a patient with Stargardt disease. Max Hodak, the former president and co-founder of Neuralink, shared details of the procedure on stage at TechCrunch Disrupt. According to reporting by TechCrunch, the company’s work utilizing the PRIMA system represents a step forward in its broader development of a novel brain-computer interface.
Context and Significance
Stargardt disease is a genetic eye disorder that causes progressive vision loss, primarily affecting the macula. Neural implants and retinal prosthesis systems like PRIMA aim to bypass damaged photoreceptors in the eye to restore functional sight by directly stimulating remaining retinal cells or neural pathways. The involvement of Max Hodak brings additional industry attention to this approach, given his prior leadership role at Neuralink, another prominent player in the brain-computer interface sector.
Unknowns and Future Outlook
Despite the announcement, several key details remain unconfirmed. The public disclosure did not specify the exact date of the surgical procedure, the current condition of the patient, or a definitive timeline for broader clinical trials. Observers will be watching to see how Science Corporation scales this technology and whether future updates will provide clinical data regarding the patient’s visual recovery.
Further announcements from the company are expected as the clinical evaluation of the PRIMA implant continues.
Lead image: Vladimir Srajber / Pexels
